TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ANGLE plc ( (GB:CLBX) ) has shared an announcement.
CelLBxHealth plc has successfully concluded an oversubscribed placing and subscription, raising approximately £6.8 million through the issuance of new shares at a discounted price. This fundraising effort is aimed at expanding the company’s operations, subject to shareholder approval at an upcoming General Meeting. The company plans to launch a Retail Offer to raise an additional £1.0 million, providing existing retail investors an opportunity to participate. The successful fundraising is expected to bolster CelLBxHealth’s market position and support its strategic initiatives in the precision CTC intelligence industry.
The most recent analyst rating on (GB:CLBX) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:CLBX Stock Forecast page.
Spark’s Take on GB:CLBX Stock
According to Spark, TipRanks’ AI Analyst, GB:CLBX is a Neutral.
ANGLE plc’s overall stock score is primarily impacted by its poor financial performance and valuation, indicating significant challenges. Technical analysis also suggests bearish momentum. While the earnings call highlighted some positive developments, the need for additional funding and adverse market conditions weigh heavily on the stock’s outlook.
To see Spark’s full report on GB:CLBX stock, click here.
More about ANGLE plc
CelLBxHealth plc is a global precision circulating tumour cell (CTC) intelligence company specializing in innovative CTC solutions for research, drug development, and clinical oncology. Its patent-protected Parsortix® platform enables the harvesting of CTCs from blood, facilitating comprehensive downstream analysis such as whole-cell imaging, proteomic profiling, and genomic workflows. The company focuses on product sales, laboratory services, and lab-developed tests, with commercial activities centered on accelerating Parsortix platform adoption and consumable sales through partnerships with CROs and clinical labs.
Average Trading Volume: 2,808,861
Technical Sentiment Signal: Sell
Current Market Cap: £5.16M
For an in-depth examination of CLBX stock, go to TipRanks’ Overview page.